Who are Monotherapy of medium dose ICS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Durezol, Arnuity Ellipta, Omnaris, Omnaris, Mifeprex, Lotemax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/monotherapy-of-medium-dose-ics.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Monotherapy of medium dose ICS — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monotherapy of medium dose ICS (Monotherapy of medium dose ICS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid (ICS). Area: Respiratory / Pulmonology.

marketed Inhaled corticosteroid (ICS) Glucocorticoid receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Monotherapy of medium dose ICS (Monotherapy of medium dose ICS) — Ajou University School of Medicine. Medium-dose inhaled corticosteroid (ICS) monotherapy reduces airway inflammation by suppressing local immune responses and decreasing inflammatory mediator production in the lungs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Monotherapy of medium dose ICS TARGET	Monotherapy of medium dose ICS	Ajou University School of Medicine	marketed	Inhaled corticosteroid (ICS)	Glucocorticoid receptor
Durezol	DIFLUPREDNATE	Novartis	marketed	difluprednate	Glucocorticoid receptor	2008-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Omnaris	Alvesco	Takeda Gmbh	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	CICLESONIDE	Covis	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Mifeprex	MIFEPRISTONE	Corcept Therap	marketed	Progestin Antagonist [EPC]	Glucocorticoid receptor	2000-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-02-01 — Omnaris · 8371292 · US
2033-05-03 — Lotemax · 9056057 · Formulation · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US
2033-05-03 — Lotemax · 10940108 · Method of Use · US
2033-05-03 — Lotemax · 9737491 · Method of Use · US
2033-05-03 — Lotemax · 9827191 · Formulation · US
2033-05-03 — Lotemax · 11872318 · Formulation · US
2033-05-03 — Lotemax · 9393213 · Formulation · US
2033-05-03 — Lotemax · 10646436 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 12115246 · Formulation · US
2033-05-03 — Lotemax · 10688045 · Formulation · US
2033-05-03 — Lotemax · 11642317 · Formulation · US
2033-05-03 — Lotemax · 10646437 · Formulation · US
2036-01-26 — Lotemax · 11534395 · Formulation · US
2036-12-23 — Lotemax · 10596107 · Formulation · US

Sponsor landscape (Inhaled corticosteroid (ICS) class)

Ajou University School of Medicine · 1 drug in this class
AstraZeneca · 1 drug in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Organon and Co · 1 drug in this class
Research in Real-Life Ltd · 1 drug in this class
SkyePharma AG · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Monotherapy of medium dose ICS — Competitive Intelligence Brief. https://druglandscape.com/ci/monotherapy-of-medium-dose-ics. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab